.jpg "Lewis H. Bender, MS, MA, MBA photo")
Founder, Chairman, CSO, President & CEO
Intensity Therapeutics
Shelton, Connecticut, United States
Lewis H. Bender is the Founder, President and CEO of Intensity Therapeutics, a late-stage clinical biotechnology company pioneering a novel immune-based drug therapy approach to treat cancer. Mr. Bender has led the Company from an idea developed to a phase 3 international clinical study that plans to enroll 333 patients with metastatic sarcoma. The company is also conducting a Phase 2/3 program with the new drug in presurgical breast cancer. The lead drug has completed two phase 2 studies that enrolled over 200 cancer patients. Mr. Bender has over 30 years of biotech and pharmaceutical development experience. He has 14 issued patents with protection in the U.S. and 38 other countries. Mr. Bender was selected by PharmaVOICE as one of the 100 most inspiring people in the life sciences in 2019 and was featured in Forbes magazine. Mr. Bender has held numerous executive positions at the drug delivery company Emisphere. He is the author of dozens of articles on various business and scientific aspects of the pharmaceutical industry, including peer-reviewed papers on the mechanisms of action of Intensity Therapeutics’ novel cancer treatment technology. Mr. Bender earned his Bachelor and Master of Science degrees in Chemical Engineering from MIT. His MBA and MA degrees are from UPENN’s Wharton Business School and UPENN’s School of Arts.
Disclosure information not submitted.
